Select therapeutic use:

Arthritis/rheumatic disorders:

Indications for: CIMZIA

Treatment of adults with moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA), or active ankylosing spondylitis (AS).

Adult Dosage:

Rotate inj site. Give by SC inj in abdomen or thigh. RA or PsA: 400mg (two 200mg inj at separate sites) on day 1, then at weeks 2 and 4, followed by 200mg every other week. Maintenance: may consider 400mg every 4 weeks. AS: 400mg (two 200mg inj at separate sites) on day 1, then at weeks 2 and 4, followed by 200mg every 2 weeks or 400mg every 4 weeks.

Children Dosage:

Not established.

Boxed Warning:

Serious infections. Malignancy.

CIMZIA Warnings/Precautions:

Increased risk of serious or fatal infections (eg, TB, bacterial sepsis, invasive fungal [treat empirically if develops], or other pathogens). Active infections: do not initiate therapy. Chronic or history of recurring infections. Conditions that predispose to infection. Travel to, or residence in, areas with endemic TB or mycoses. Test/treat latent TB or history of, those having risk factors for TB, and HBV infection prior to initiating therapy. Monitor closely if new infection, active TB (even if initial latent test is negative), reactivation of HBV, or blood dyscrasias occurs; discontinue if serious infection, sepsis, HBV reactivation, or hematological abnormality develops. History of histoplasmosis exposure. Lymphoma and other malignancies. Perform periodic skin exams (esp. those with skin cancer risk factors). Immunosuppressed. Pre-existing or recent-onset demyelinating disorders (eg, multiple sclerosis, Guillain-Barré syndrome). CHF (monitor). Discontinue if lupus-like syndrome with antibody formation or serious hypersensitivity reaction occurs. Latex allergy (needle shield). Pregnancy. Nursing mothers.

CIMZIA Classification:

Tumor necrosis factor (TNF) blocker.

CIMZIA Interactions:

Concomitant anakinra, abatacept, rituximab, etanercept, natalizumab, live or attenuated vaccines, other biological DMARDs or TNF blockers: not recommended. Immunosuppressants increase risk of infection. May interfere with coagulation tests (eg, aPTT).

Adverse Reactions:

Upper respiratory infections, rash, UTI; TB, HBV reactivation, other infections, malignancies (eg, lymphoma; esp. children), heart failure; rare: hypersensitivity reactions, neurological disorders, lupus-like syndrome with antibody formation.

Generic Drug Availability:

NO

How Supplied:

Pack—1 (2 single-dose vials w. syringes, needles, supplies); Single-dose prefilled syringes—2 (w. supplies); Prefilled Syringe Starter Kit—6 (w. supplies)

Pricing for CIMZIA

starter of 200mg/ml kit (Qty: 1)
Appx. price $4922
GoodRx

Colorectal disorders:

Indications for: CIMZIA

In moderately-to-severely active Crohn's disease: to reduce signs and symptoms and to maintain clinical response in adult patients with inadequate response to conventional therapy.

Adult Dosage:

Rotate inj site. Give by SC inj in abdomen or thigh. 400mg (two 200mg inj at separate sites) on day 1, then at weeks 2 and 4; maintenance 400mg every 4 weeks.

Children Dosage:

Not established.

Boxed Warning:

Serious infections. Malignancy.

CIMZIA Warnings/Precautions:

Increased risk of serious or fatal infections (eg, TB, bacterial sepsis, invasive fungal [treat empirically if develops], or other pathogens). Active infections: do not initiate therapy. Chronic or history of recurring infections. Conditions that predispose to infection. Travel to, or residence in, areas with endemic TB or mycoses. Test/treat latent TB or history of, those having risk factors for TB, and HBV infection prior to initiating therapy. Monitor closely if new infection, active TB (even if initial latent test is negative), reactivation of HBV, or blood dyscrasias occurs; discontinue if serious infection, sepsis, HBV reactivation, or hematological abnormality develops. History of histoplasmosis exposure. Lymphoma and other malignancies. Perform periodic skin exams (esp. those with skin cancer risk factors). Immunosuppressed. Pre-existing or recent-onset demyelinating disorders (eg, multiple sclerosis, Guillain-Barré syndrome). CHF (monitor). Discontinue if lupus-like syndrome with antibody formation or serious hypersensitivity reaction occurs. Latex allergy (needle shield). Pregnancy. Nursing mothers.

CIMZIA Classification:

Tumor necrosis factor (TNF) blocker.

CIMZIA Interactions:

Concomitant anakinra, abatacept, rituximab, etanercept, natalizumab, live or attenuated vaccines, other biological DMARDs or TNF blockers: not recommended. Immunosuppressants increase risk of infection. May interfere with coagulation tests (eg, aPTT).

Adverse Reactions:

Upper respiratory infections, rash, UTI; TB, HBV reactivation, other infections, malignancies (eg, lymphoma; esp. children), heart failure; rare: hypersensitivity reactions, neurological disorders, lupus-like syndrome with antibody formation.

Generic Drug Availability:

NO

How Supplied:

Pack—1 (2 single-dose vials w. syringes, needles, supplies); Single-dose prefilled syringes—2 (w. supplies); Prefilled Syringe Starter Kit—6 (w. supplies)

Pricing for CIMZIA

starter of 200mg/ml kit (Qty: 1)
Appx. price $4922
GoodRx

Psoriasis:

Indications for: CIMZIA

Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Adult Dosage:

Rotate inj site. Give by SC inj in abdomen or thigh. 400mg (two 200mg inj at separate sites) every other week. If ≤90kg: may consider 400mg on day 1, then at weeks 2 and 4, followed by 200mg every other week.

Children Dosage:

Not established.

Boxed Warning:

Serious infections. Malignancy.

CIMZIA Warnings/Precautions:

Increased risk of serious or fatal infections (eg, TB, bacterial sepsis, invasive fungal [treat empirically if develops], or other pathogens). Active infections: do not initiate therapy. Chronic or history of recurring infections. Conditions that predispose to infection. Travel to, or residence in, areas with endemic TB or mycoses. Test/treat latent TB or history of, those having risk factors for TB, and HBV infection prior to initiating therapy. Monitor closely if new infection, active TB (even if initial latent test is negative), reactivation of HBV, or blood dyscrasias occurs; discontinue if serious infection, sepsis, HBV reactivation, or hematological abnormality develops. History of histoplasmosis exposure. Lymphoma and other malignancies. Perform periodic skin exams (esp. those with skin cancer risk factors). Immunosuppressed. Pre-existing or recent-onset demyelinating disorders (eg, multiple sclerosis, Guillain-Barré syndrome). CHF (monitor). Discontinue if lupus-like syndrome with antibody formation or serious hypersensitivity reaction occurs. Latex allergy (needle shield). Pregnancy. Nursing mothers.

CIMZIA Classification:

Tumor necrosis factor (TNF) blocker.

CIMZIA Interactions:

Concomitant anakinra, abatacept, rituximab, etanercept, natalizumab, live or attenuated vaccines, other biological DMARDs or TNF blockers: not recommended. Immunosuppressants increase risk of infection. May interfere with coagulation tests (eg, aPTT).

Adverse Reactions:

Upper respiratory infections, rash, UTI; TB, HBV reactivation, other infections, malignancies (eg, lymphoma; esp. children), heart failure; rare: hypersensitivity reactions, neurological disorders, lupus-like syndrome with antibody formation.

Generic Drug Availability:

NO

How Supplied:

Pack—1 (2 single-dose vials w. syringes, needles, supplies); Single-dose prefilled syringes—2 (w. supplies); Prefilled Syringe Starter Kit—6 (w. supplies)

Pricing for CIMZIA

starter of 200mg/ml kit (Qty: 1)
Appx. price $4922
GoodRx